|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Combination therapy with the CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistically reduces JMJD6, E2F2, N-Myc, c-Myc expression, induces apoptosis in vitro and leads to neuroblastoma tumor regression in mice, which are significantly reversed by forced JMJD6 over-expression.
|
31346162 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These results reveal a previously unrecognized role for Livin in regulating the tumor-initiating capacity in colon cancer and provide a novel treatment strategy in cancer via the interruption of H2A.X<sup>Y39ph</sup> function and the interaction between H2A.X<sup>Y39ph</sup> and JMJD6.
|
31445935 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Indeed, triple transgenic fish engineered to express a microRNA-resistant Jmjd6 from the onset of melanoma have increased tumor burden, higher infiltration of leukocytes and shorter melanoma-free survival.
|
30619488 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In tumor samples but not normal breast tissue, the expression of JMJD6 linearly correlated with HOTAIR suggesting that JMJD6-mediated up-regulation may occur specifically in tumors.
|
29229759 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We first showed that miR-770 was downregulated in NSCLC tissues and cell lines, and the low expression of miR-770 was correlated with poor patient survival in NSCLC patients. miR-770 acted on a tumor suppressor by binding to the 3'UTR of JMJD6 and downregulated its expression in NSCLC cells.
|
28882645 |
2017 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
JMJD6 overexpression in MMTV-Myc cell lines increases tumor burden, induces EMT, and greatly enhances tumor metastasis.
|
27081402 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
JMJD6 silencing in breast tumoural cells promotes certain characteristics of tumourigenesis including proliferation, migration in vitro, and tumour growth in vivo.
|
25951181 |
2015 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
JMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like, Claudin-low, Her2-enriched, and ER+ Luminal B tumors.
|
22621393 |
2012 |